Company intelligence / Profile preview

Throne Biotechnologies

Paramus, New Jersey, United States

Ownership: Private
Employees: ~17
Development stage: Phase 2

Overview

Over 10 years of clinical studies in Spain, China, and the United States have demonstrated clinical safety and efficacy in more than 200 patients aged 3-70 years. 70% of type 1 and type 2 diabetic patients demonstrated clinical efficacy with many patients reducing insulin and some becoming insulin independent[3][6].

Therapeutic areas: EndocrinologyImmunologyDermatologyInfectious Diseases
Modalities: Stem cell therapy
Industry: Biotech

Drug pipeline

1 asset

Stem Cell Educator Therapy

Partnerships

Fresenius Medical Care

Beyond the preview

Go deeper on Throne Biotechnologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Throne Biotechnologies.

Explore the full profile